Nkarta
NKTX on Nasdaq. Nkarta makes off-the-shelf engineered NK cell therapies for patients with autoimmune diseases. Market value $181m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-56.76 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$2.31 a share, 36% above its 1-year low
Over the past year the price has ranged from $1.70 to $3.72.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | n/a | $0 | $0 |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.05bn | 0.05bn | 0.07bn | 0.07bn | 0.07bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)1 of 7 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 47% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $40 million, compared with a loss of $23 million a year ago.
- Over the past 12 months it spent $94 million more cash than it brought in, compared with $100 million a year earlier.
- 1% more shares than a year ago. Each share owns a bit less of the company.
| Quarter to | Amount |
|---|---|
| September 2024 | -$28m |
| December 2024 | -$26m |
| March 2025 | -$32m |
| June 2025 | -$23m |
| September 2025 | -$22m |
| December 2025 | -$27m |
| March 2026 | -$28m |
| June 2026 | -$40m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 25 March 2026
- Next quarterly (estimated, 10-Q)
- 9 November 2026
Who owns it
None of the long-term investors we follow own it. 136 funds in all.
Largest holders overall
- RA Capital Management, L.P.$31m
- BlackRock$18mAdded
- NEA Management Company$10m
- Samsara Biocapital$10m
- SR One Capital Management, LP$9m
- GSK$9m
- Monaco Asset Management SAM$7mCut
- Vanguard Capital Management$6mAdded
- Citadel Advisors$6mAdded
- TWO Sigma Investments, LP$5mCut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- New Enterprise Associates 15, L.P.Passive investorat least 4.9%(filed with 6 related holders)Since 19 May 2026
What they said
NEA 15 acquired the NEA 15 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 15 and other Reporting Persons may dispose of or acquire additional shares of the Issuer.…
Read the filing - Samsara BioCapital, L.P.Passive investorat least 4.9%(filed with 2 related holders)Since 20 November 2025
- Kenneth GriffinPassive investorat least 4.1%(filed with 6 related holders)Since 30 September 2025
- LSP 6 Management B.V.Passive investorat least 4.0%(filed with 2 related holders)Since 12 February 2025
- TANG CAPITAL MANAGEMENT, LLCPassive investorat least 2.1%−7.8 pts(filed with 5 related holders)Since 31 December 2025
- BlackRock, Inc.Passive investorSold down below 5%Since 30 September 2025
- COMMODORE CAPITAL LPPassive investorSold down below 5%Since 31 December 2024
- Adage Capital Partners GP, L.L.C.Passive investorSold down below 5%Since 31 December 2024
| Holder | Stake | Since | |
|---|---|---|---|
New Enterprise Associates 15, L.P. Passive investor | at least 4.9% (filed with 6 related holders) | 19 May 2026 | What they saidNEA 15 acquired the NEA 15 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 15 and other Reporting Persons may dispose of or acquire additional shares of the Issuer.… Read the filing |
Samsara BioCapital, L.P. Passive investor | at least 4.9% (filed with 2 related holders) | 20 November 2025 | |
Kenneth Griffin Passive investor | at least 4.1% (filed with 6 related holders) | 30 September 2025 | |
LSP 6 Management B.V. Passive investor | at least 4.0% (filed with 2 related holders) | 12 February 2025 | |
TANG CAPITAL MANAGEMENT, LLC Passive investor | at least 2.1%−7.8 pts (filed with 5 related holders) | 31 December 2025 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 September 2025 | |
COMMODORE CAPITAL LP Passive investor | Sold down below 5% | 31 December 2024 | |
Adage Capital Partners GP, L.L.C. Passive investor | Sold down below 5% | 31 December 2024 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 2 sold $70,422.
- HASTINGS PAUL JChief Executive Officer, DirectorSold
- Date
- 18 June 2026
- Shares
- 1,776
- Price
- $2.71
- Value
- $4,813
- HASTINGS PAUL JChief Executive Officer, DirectorSold
- Date
- 15 January 2026
- Shares
- 26,046
- Price
- $2.07
- Value
- $53,915
- Mahmood NadirPresidentSold
- Date
- 15 January 2026
- Shares
- 5,649
- Price
- $2.07
- Value
- $11,693
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 18 June 2026 | HASTINGS PAUL J Chief Executive Officer, Director | Sold | 1,776 | $2.71 | $4,813 |
| 15 January 2026 | HASTINGS PAUL J Chief Executive Officer, Director | Sold | 26,046 | $2.07 | $53,915 |
| 15 January 2026 | Mahmood Nadir President | Sold | 5,649 | $2.07 | $11,693 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 25 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 4 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.